News
TipRanks on MSN2d
Pfizer’s Phase 3 Study on Elranatamab vs. Lenalidomide: A Potential Game-Changer in Multiple Myeloma TreatmentPfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 study titled A RANDOMIZED, 2-ARM, ...
In the U.S., MONJUVI® (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or ...
Bristol Myers Squibb (NYSE: BMY) has posted better-than-expected second-quarter 2025 results, driven by strong sales of its ...
TipRanks on MSN3d
Regeneron’s Phase 3 Trial: A New Hope for Lymphoma Treatment?Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is conducting a Phase 3 ...
The European Commission (EC) has granted approval to Sanofi's Sarclisa in combination with a regimen of VRd for multiple myeloma.
Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...
Paris: Sanofi has announced that the European Commission has approved Sarclisa in combination with bortezomib, lenalidomide, ...
London: GSK plc has received approval for Blenrep in the European Union (EU) for the treatment of adults with relapsed or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback